Who Is a Candidate, and Who Should Not Use It Semaglutide is generally considered for adults managing excess weight or related metabolic goals, alongside nutrition and activity changes, when a provider judges the benefits outweigh the risks for that person
In May 2026, Innogen announced it will present full Phase IIb results from its ENLIGHT clinical trial at the 2026 American Diabetes Association (ADA) Scientific Sessions
Many users suspect dehydration , which can occur when appetite drops and thirst cues diminish
LegitScript verified Active members: 150,000+ The full medication menu includes compounded semaglutide and tirzepatide injections, GLP-1 liquid drops, GLP-1 lozenges, oral semaglutide liposomal tablets, the FDA-approved Foundayo pill, brand-name Wegovy and Zepbound, plus several non-GLP-1 weight-loss medications like metformin, naltrexone-bupropion, and topiramate combinations